β³ Fetching live dividend data...
Home βΊ Calculator βΊ RCTFF Dividend Calculator 2026
Rochester Resources Ltd. Β· OTC
Price: $0.15 Β· Annual div: $2.00/share Β· Frequency: quarterly Β· Payout ratio: 50% Β· Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in RCTFF β $1810702976566278.00M in 10 years Β· $150,329,243,793,787,500,000.00/month
Rochester Resources Ltd., a junior natural resource company, engages in the acquisition, exploration, and development of mineral properties in Mexico. It primarily explores for gold and silver deposits. The company holds 100% interest in the Mina Real property that consists of 11 mining concessions and one mineral claim covering approximately 21,367.42 hectares; and the San Francisco property, which includes twelve mining concessions covering an area of 18,125.05 hectares. It also has an agreement to acquire a 70% interest in the Santa Fe property that comprises one mining concession covering approximately 3,852.66 hectares. Rochester Resources Ltd. was incorporated in 1989 and is headquartered in Vancouver, Canada.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime.
Ready to invest? Open RCTFF position with:
Real after-tax yield depends on where you live and how you hold RCTFF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| πΊπΈ Roth IRA / 401k | 0% | 1369.86% | 1367.06% | $136,986 / yr |
| πΊπΈ US Taxable (15%) β | 15% | 1164.38% | 1161.58% | $116,438 / yr |
| πΊπΈ US Taxable (20%) | 20% | 1095.89% | 1093.09% | $109,589 / yr |
| π¬π§ UK ISA | 0% | 1369.86% | 1367.06% | $136,986 / yr |
| π¬π§ UK Taxable | 8.75% | 1250.00% | 1247.20% | $125,000 / yr |
| π¨π¦ TFSA | 0% | 1369.86% | 1367.06% | $136,986 / yr |
| π¨π¦ CA Taxable | 25% | 1027.39% | 1024.60% | $102,739 / yr |
| π¦πΊ Super (pension) | 15% | 1164.38% | 1161.58% | $116,438 / yr |
| π¦πΊ AU Taxable | 30% | 958.90% | 956.10% | $95,890 / yr |
| π©πͺ DE Taxable | 26.375% | 1008.56% | 1005.76% | $100,856 / yr |
| π«π· FR Taxable | 30% | 958.90% | 956.10% | $95,890 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr Β· πΊπΈ US Taxable (15%) Β· static projection (no growth assumed).
RCTFF pays quarterly β 4 times per year. Next ex-div: TBD.
How RCTFF compares to typical S&P 500 Average averages. (Sector "Basic Materials" not matched β using S&P 500 average)
Benchmarks: S&P 500 sector averages (2024β2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RCTFF sourced from FMP /financial-growth endpoint β real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores β lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RCTFF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer β